Recursion Pharmaceuticals, Inc. (RXRX) Stock Price & Analysis

Recursion Pharmaceuticals, Inc. (RXRX) is trading at USD 4.23, down 2.76% today, as of October 29, 2026 at 19:41 UTC (US market open; quotes may be delayed), according to Nexqual market data.

RXRX last closed at USD 4.35; today's session has ranged USD 4.15–4.52 on volume of 17,247,625 shares. Market capitalization is $2.53B, with a 52-week range of USD 2.77–5.84 (NMS). Source: Nexqual, retrieved October 29, 2026 at 19:42 UTC.

Also available as compact Markdown for AI agents: nexqual.com/RXRX.md

Key facts (RXRX)

• Last four reported quarters (through Jun 30, 2026): revenue $54.9M, net income -$519M (-945.9% margin), free cash flow -$352M (SEC filings).
• Insider open-market sales, last ~7 months: 15 Form 4 filings, $1.7M; 0 not under a Rule 10b5-1 plan ($0K); 6 by opportunistic insiders (0 outside 10b5-1 plans), 4 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.29 on a 1–5 scale) (7 analysts), mean target USD 7.32 (range 4–10).
• Total return with dividends: 1Y -27.9% vs S&P 500 +13.0%; 5Y -77.9% vs S&P 500 +78.9%.
• Next earnings: 2026-11-02, EPS estimate USD -0.23, revenue estimate $14.8M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RXRX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (RXRX)

P/S 46.1x · EV/Sales 36.2x · P/B 2.8x · FCF yield -13.93% · Earnings yield -20.52% · Net cash $541M · EV $1.99B

Insider sales (SEC Form 4, open-market, last ~7 months) (RXRX)

15 of 15 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (RXRX)

Consensus Buy (mean 2.29 on a 1–5 scale), 7 analysts; mean target USD 7.32 (low 4, high 10).

Rating changes, last 120 days:

Total return (dividends reinvested) (RXRX)

RXRX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

RXRX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

RXRX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 25, 2026.

Companies that name RXRX in their SEC reports

RXRX analyst estimates and revisions

RXRX options: expected move

Options price a move of about ±13.6% (±$0.57) by Nov 6, 2026, which includes earnings on Nov 2, 2026. Over the last 8 reports the stock moved ±9.4% on average.

30-day implied volatility 97.3% vs 110.8% realized over the last 30 trading days. Put/call ratio (volume) 0.13. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 19:42 UTC)

Technical Analysis (RXRX)

Nexqual's technical model rates RXRX "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of October 29, 2026 at 19:42 UTC.

Analyst Ratings (RXRX)

Wall Street analysts rate RXRX "Buy" based on 7 analysts, with a mean price target of USD 7.32 (range USD 4–10), per Nexqual as of October 29, 2026 at 19:42 UTC.

Earnings (RXRX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 19:42 UTC.

Financials & Fundamentals (RXRX)

Source: Nexqual, October 29, 2026 at 19:42 UTC.

Financial Health Score (RXRX)

Nexqual rates Recursion Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 19:42 UTC.

Ownership (RXRX)

Source: Nexqual, October 29, 2026 at 19:42 UTC.

Leadership (RXRX)

Recursion Pharmaceuticals, Inc. is led by Najat Khan, CEO, President & Director, per Nexqual as of October 29, 2026 at 19:42 UTC.

Major Backers & Investors (RXRX)

Notable institutional backers of Recursion Pharmaceuticals, Inc. include ARK Invest, Baillie Gifford, Softbank Group Corporation, according to Nexqual as of October 29, 2026 at 19:42 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 19:42 UTC.

From Recursion Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• The strength of our platform is not defined by a single asset or model, but by the scale and quality of our core capabilities and underlying infrastructure, including: •Proprietary Data: We have generated one of the largest relatable data sets in biopharma using our automated high throughput labs, which can run over 2 million experiments per week.
• Recursion combines proprietary multimodal data, purpose-built models and compute, and our bilingual teams and culture to create the first AI-native, end-to-end platform spanning idea through the clinic.
• We have built an end-to-end, AI-native platform that spans biological discovery, small molecule design, and clinical development, and our strategy is to continue investing selectively in capabilities that improve the probability of success, speed, and confidence of scientific and clinical decision-making.
• Through our partnerships with leading pharmaceutical companies including Roche and Genentech, Sanofi, Bayer, and Merck KGaA (Darmstadt, Germany), we have secured more than $500 million in upfront and progress-based milestone payments to date, with the potential for over $20 billion in additional milestones before royalties.

Partnerships

• Roche and Genentech: Turning novel insights from proprietary digital maps of complex biology into potential novel therapeutics •Neuron Map: In partnership with Roche and Genentech, Recursion built the first whole-genome CRISPR knockout map generated from a subset of 1 trillion internally manufactured iPSC-derived neuronal cells ($30 million milestone payment, accepted in 2024).
• We largely train models using our own supercomputer, BioHive-2, one of the largest supercomputers in biopharma, built in collaboration with NVIDIA. •People & Culture: A core differentiator is our people and culture—a unique, "bilingual" team of experts fluent in both life sciences (biology/chemistry) and technology (data science/engineering).

Legal & Regulatory Risks (Item 1A, quoted)

• We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize our product candidates.
• The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
• The acceptance of study data by the FDA, EMA or other comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions.
• We may submit marketing applications in countries other than the United States.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 19:42 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt